---
schema_version: "secwatch.filing_event.v1"
accession: "0001999480-24-000020"
form_type: "8-K"
ticker: "ANRO"
cik: "0001999480"
company_name: "Alto Neuroscience, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:24:31.190225+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Alto Neuroscience Q1 net loss $13.4M; cash $205.9M; pipeline on track for multiple readouts

## Summary
- Net loss $13.4M vs $7.3M YoY; R&D expenses $10.0M, G&A $4.4M, both up on clinical study costs and public company expenses.
- Cash and equivalents $205.9M as of March 31, 2024; expects to fund operations into 2027.
- Initiated Phase 2 study of ALTO-203 in MDD with anhedonia; reported positive Phase 1 data for transdermal ALTO-101 with improved tolerability.
- Phase 2b studies of ALTO-100 and ALTO-300 in MDD enrolling; topline data for ALTO-100 expected 2H 2024, ALTO-300 1H 2025.

## SEC filing metadata
- accession: 0001999480-24-000020
- form_type: 8-K
- ticker: ANRO
- cik: 0001999480
- company_name: Alto Neuroscience, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1999480/000199948024000020/0001999480-24-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1999480/000199948024000020/alto-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999480-24-000020
- JSON: https://secwatch.observer/filing/0001999480-24-000020.json
- Plain text: https://secwatch.observer/filing/0001999480-24-000020.txt

## Key facts
- Earnings Releases
  Alto Neuroscience, Inc. reported financial results for the first quarter ended March 31, 2024.
  - Period: the first quarter ended March 31, 2024
  - Result: reported results
  source text: Alto Neuroscience, Inc. (the "Company") reported financial results for the fiscal quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1999480/000199948024000020/0001999480-24-000020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.